Active immunization of humans with dendritic cells

Journal of Clinical Immunology

Volumn 20, Issue 3, 2000, Pages 167-174

  Dhodapkar, M V ^a   Bhardwaj, N ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Antiviral immunity; Cytolytic T cells; Dendritic cells; Immunotherapy; Tumor immunology

Indexed keywords

ACTIVE IMMUNIZATION; ANTIGEN PRESENTATION; ARTICLE; CANCER; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOTHERAPY; INFECTION; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

ANTIGENS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL SURVIVAL; COMMUNICABLE DISEASES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; VACCINATION;

EID: 0033944443     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006681312249     Document Type: Article

References (65)

1. Fully mobilizing host defense: Building better vaccines
2. Principles for adoptive T cell therapy of human viral diseases
3. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
4. Dendritic cells and the control of immunity
5. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
6. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
7. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A020-specific peptides from prostate-specific peptides from prostate-specific membrane antigen
8. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
9. Mature dendritic cells boost functionally superior T cells in humans without foreign helper epitopes
10. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma
11. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T canells and induces regression of some metastases in advanced stage IV melanoma
12. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
13. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
14. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
15. Dendritic cell-based immunotherapy of renal cell carcinoma
16. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy
17. Antigen capture, processing, and presentation by dendritic cells: Recent cell biological studies
18. Origin, maturation and antigen presenting function of dendritic cells
19. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α
20. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ
21. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells
22. + T-helper and a T-killer cell
23. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
24. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
25. + T cells
26. + cytolytic T cell responses
27. Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus
28. Vaccinia virus inhibits the maturation of human dendritic cells: A novel mechanism of immune evasion
29. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
30. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization
31. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73
32. Receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells
33. Tumor-specific killer cells in paraneoplastic cerebellar degeneration
34. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells
35. Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability
36. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
37. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells
38. + T cells and process soluble antigen
39. + TNFα
40. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
41. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients
42. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
43. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group
44. Phenotypic analysis of antigen-specific T lymphocytes
45. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen
46. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
47. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation
48. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors
49. Reciprocal control of T helper cell and dendritic cell differentiation
50. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Thl-biasing cytokines IL-12 and IFN-alpha
51. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells
52. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
53. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation
54. Migration of leukocytes across endo thelium and beyond: Molecules involved in the transmigration and fate of monocytes
55. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells
56. The role of CD4+ T cell responses in antitumor immunity
57. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
58. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen
59. Migration of human dendritic cells after injection in patients with metastatic malignancies
60. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells
61. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection
62. In vivo migration of dendritic cells differentiated in vitro: A chimpanzee model
63. CD40 and CD154 in cell-mediated immunity
64. TRANCE (tumor necrosis factor (TNF)-related activation-induced cytokine), anew TNF family member predominantly expressed in T cells, is a dendritic cell specific survival factor
65. Interaction of dendritic cells with skin endothelium: A new perspective on immunosurveillance